B. Braun gets FDA approval for chemical-free dialysis machine

Bethlehem-based B. Braun Medical Inc., a self-described leader in smart infusion therapy and pain management, announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its AQUAbase nX Reverse Osmosis System.

The AQUAbase nX is a single-stage reverse osmosis device providing high-quality water for dialysis patients without the use of chemicals, according to a release. “Through its unique design, AQUAbase nX has up to a 75% raw water conversion rate that may conserve water usage and reduce costs of power, pre-treatment and maintenance of equipment.”

The system’s stainless-steel piping is designed to achieve the lowest possible dead space in the main ring, which may prevent microbial contamination. With systems ranging in capacity, AQUAbase nX is a compact and customizable solution for hospitals, dialysis centers or skilled nursing facilities that have anywhere from five to 18 chairs for dialysis patients. The system’s 7-inch touchscreen display provides direct access to relevant settings and an up-to-date status bar.

“We are excited to broaden our portfolio of high-quality hemodialysis products with the AQUAbase nX,” said Jonathan Stapley, senior director of marketing, active devices. “We now have a compact solution for smaller facilities that has heat disinfection to reduce the need for chemicals.”

B. Braun Medical Inc. is part of the B. Braun Group of Companies in the U.S., which employs 8,500 people at over 30 locations across North America. Globally, the B. Braun Group of Companies employs more than 64,000 people in 64 countries.

Paula Wolf is a freelance writer